Get the Stockscreener App
121.59
0.86%
-1.05
After Hours:
120.55
-1.04
-0.86%
Jazz Pharmaceuticals Plc stock is traded at $121.59, with a volume of 277.64K.
It is down -0.86% in the last 24 hours and up +8.65% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$122.64
Open:
$122.89
24h Volume:
277.64K
Relative Volume:
0.40
Market Cap:
$7.35B
Revenue:
$3.91B
Net Income/Loss:
$394.92M
P/E Ratio:
-77.45
EPS:
-1.57
Net Cash Flow:
$1.02B
1W Performance:
-4.01%
1M Performance:
+8.65%
6M Performance:
+16.63%
1Y Performance:
+6.42%
1-Day Range:
$121.05
$123.18
1-Week Range:
$120.31
$128.41
52-Week Range:
$99.06
$134.17
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
121.59 | 7.35B | 3.91B | 394.92M | 1.02B | 5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Charles Schwab Investment Management Inc. Purchases 42,587 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Cerity Partners LLC Buys 18,414 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Thrivent Financial for Lutherans Lowers Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Intech Investment Management LLC Reduces Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
JAZZ (Jazz Pharmaceuticals) Enterprise Value : $10,998 Mil (As of Nov. 29, 2024) - GuruFocus.com
Vestal Point Capital LP Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Bridgewater Associates LP Has $12.59 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Oligonucleotide Delivery System Market Top PlayersBiogen, - openPR
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy? - Yahoo Finance
8 Most Undervalued Pot Stocks to Buy According to Analysts - Insider Monkey
Jazz Pharmaceuticals expands credit facility, extends maturity date By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals expands credit facility, extends maturity date - Investing.com India
Cerebral Palsy Market to Show Remarkable Growth Trends from 2024 - openPR
FDA approves Roche’s PATHWAY HER2 test for biliary tract cancer - Medical Device Network
Connor Clark & Lunn Investment Management Ltd. Sells 5,102 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera - MSN
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer - MSN
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky (AVDL) - Seeking Alpha
HC Wainwright Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - MarketBeat
8,969 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Valence8 US LP - MarketBeat
Jazz secures FDA nod for Ziihera to treat HER2-positive biliary tract cancer - World Pharmaceutical Frontiers
Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler - Yahoo Finance
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 9,134 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
B.C. biotech Zymeworks gets FDA approval for new cancer drug - Business in Vancouver
FDA approves biliary tract cancer treatment from Jazz - BioWorld Online
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - MSN
JAZZ Secures FDA Approval For Ziihera In Biliary Tract Cancer - Barchart
U.S. STOCKS Jazz Pharmaceuticals, SPAR, Alphabet - XM
Jefferies raises Jazz Pharmaceuticals stock target, holds buy on potential By Investing.com - Investing.com UK
Pacer Advisors Inc. Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Thompson Siegel & Walmsley LLC Acquires 59,685 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
John G Ullman & Associates Inc. Sells 11,400 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals stock trades at discount amid diversification efforts By Investing.com - Investing.com UK
Jazz stock Zymeworks stock gain on FDA nod (JAZZ:NASDAQ) - Seeking Alpha
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewswire Inc.
JAZZ (Jazz Pharmaceuticals) COGS-to-Revenue : 0.11 (As of Sep. 2024) - GuruFocus.com
JAZZ (Jazz Pharmaceuticals) EPS without NRI : $19.61 (TTM As of Sep. 2024) - GuruFocus.com
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment - Reuters.com
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - Lelezard
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment - MSN
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference - StockTitan
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? - Yahoo Finance
Jazz Pharmaceuticals shares target raised on patient base growth - Investing.com
Jazz Pharmaceuticals: High Uncertainty, Low Risk (undefined:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals shares target raised on patient base growth By Investing.com - Investing.com UK
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Robert W. Baird Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $162.00 - MarketBeat
Victory Capital Management Inc. Has $28.22 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View - MSN
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):